Sai Parenterals, through subsidiary SP Analytics, is acquiring a majority stake in Hyderabad-based branded formulations prescription business company Bion Therapeutics India for an undisclosed sum.
It will be an all-cash deal and a definitive agreement to acquire the stake has been signed. On completion, which is expected by this month, Bion will become a step-down subsidiary, Sai Parenterals said on Tuesday.
The acquisition will add 16 established brands and around 250 field staff, strengthening its presence in India’s prescription market, Sai Parenterals said. Further, its manufacturing capability would create value addition to Bion.
Bion’s portfolio is manufactured from contract manufacturers across several locations. Post acquisition, the production will move progressively into Sai Parenterals’ own facilities, which hold TGA-Australia and WHO-GMP accreditations. This gives the brands assured supply, consistent quality and improved margins, without reliance on contract manufacturers, Sai said.
“Over the past year we have expanded capacity at Unit III, begun construction of the critical-care injectable facility at Gummadidala, consolidated our research at Sai Prathyak and strengthened the Noumed platform in Australia and New Zealand. Each of these strengthens what we are able to develop and manufacture. Bion provides the route to take them to the Indian market directly,” said Anil Kumar Karusala, chairman and managing director of Sai Parenterals.
Published – November 17, 2026 09:25 pm IST
Leave a Reply